Under a standard YC post-money SAFE with no side letters, a SAFE investor has almost no ability to block a Series A financing. The SAFE converts automatically upon the closing of a qualified financing — the investor does not need to consent to the conversion or to the terms of the new round. Blocking rights, if any exist, would need to come from a separately negotiated side letter or from a non-standard SAFE.
This is the most important thing to understand, and I typically tell founders this upfront when they call me in a panic about a SAFE investor making demands: the standard YC post-money SAFE does not give the investor a vote on the next financing. It does not give them approval rights over the round terms. It does not give them the ability to prevent conversion. The SAFE is a debt-like instrument that converts to preferred stock upon a qualified financing, and that conversion happens automatically when the round closes. The investor cannot simply refuse to convert and remain a creditor. What they can do is dispute whether the conversion has been calculated correctly, assert rights under any side letters they negotiated at the time of the SAFE, or try to create enough noise with your Series A lead that it makes your lead nervous. Those are the real risks to manage — not a legal blocking right the investor probably doesn't have.
A SAFE investor's legal leverage is limited to rights explicitly in their SAFE or side letter — most commonly pro-rata rights to participate in the new round, most-favored-nation clauses that entitle them to better terms if later SAFEs got them, and information rights. None of these create a blocking right, but pro-rata rights create a participation obligation that, if ignored, can give the investor a breach of contract claim.
In my experience, when a SAFE investor claims they can "block" a round, what they often mean in practice is one of three things. First, they have a pro-rata right — the right to participate in the new round up to their pro-rata ownership percentage — and they are threatening to assert it aggressively or to create a dispute about its calculation. This is a real right, but it is a participation right, not a blocking right. If you want to honor it, you can. If you don't, they have a breach of contract claim, not a veto. Second, they have an MFN clause in their SAFE — a most-favored-nation provision that says if later SAFEs were issued on better terms (lower valuation cap, higher discount), they are entitled to those better terms. If you failed to comply with an MFN clause, they may have a legitimate grievance. Third, they have information rights that were either violated or that they're using as a platform to inject themselves into your Series A process. None of these create an actual blocking right over your financing. The conversation about what they can legally do is usually much shorter than founders expect — and then the harder conversation is about what they will do, even without legal authority, to create friction.
The most common demands are: conversion at a better valuation cap than the SAFE provides, cash buyout at a premium rather than conversion, additional equity as consideration for "cooperating," pro-rata participation rights they weren't originally given, and anti-dilution protection on conversion. None of these demands are legally required to be honored absent express agreement in the original SAFE or a side letter.
I've seen this scenario many times. A founder raises a $500K SAFE at a $5 million cap in 2022. The company is now raising a $10 million Series A at a $40 million pre-money valuation. The SAFE investor realizes they're about to convert at a significant dilution relative to where the company has landed, and they want a better deal. The specific demands vary, but the pattern is consistent: they ask for conversion at a lower cap (say $2 million instead of $5 million, which is economically incoherent), or they ask for the company to buy them out at a 3x on their investment rather than converting, or they demand new pro-rata rights in the Series A that their SAFE doesn't provide. The founder, anxious not to blow up the round and uncertain about their legal obligations, often considers accommodating these demands. I typically advise against unilateral accommodation without thinking through the consequences carefully: if you give one SAFE investor better terms, you may have MFN obligations to other SAFE investors, you may create precedent your Series A lead will question, and you may create a cap table anomaly that creates complications in future rounds. The answer is not to ignore the investor — it is to engage them directly, explain what the SAFE actually says, and have an honest conversation about what a reasonable resolution looks like.
The negotiation with a difficult SAFE investor should be direct, documented, and time-bounded. Founders should explain the SAFE's actual conversion mechanics, address any legitimate claims (MFN, pro-rata), offer a reasonable accommodation if there is a genuine grievance, and set a clear deadline for resolution. Dragging a SAFE dispute into the final days of a Series A closing creates leverage for the investor that they would not otherwise have.
The most dangerous thing founders do in this situation is avoid the conversation. They hope the SAFE investor will go away, or they put off engaging until the last week of their Series A closing, at which point the investor has maximum leverage because any delay is now the founder's problem. I typically advise engaging directly and early — ideally before the term sheet is signed, so the SAFE investor knows what's coming and has time to process it. The conversation should cover: what the SAFE says (and what it doesn't say), what their pro-rata rights are and whether you intend to honor them, whether there is an MFN claim and what it entitles them to, and what the company is willing to offer as a reasonable accommodation if there is a genuine grievance. If the investor's only claim is that they don't like the terms of their SAFE and wish they had negotiated it differently, the answer is that you will honor the SAFE as written, and that accommodating their request would be unfair to other SAFE investors who received the same terms without complaints. If they have a legitimate MFN claim or their pro-rata was inadvertently excluded, address it directly — those are fixable problems. What founders should not do is agree to economically significant changes to the SAFE terms under pressure, because those concessions may create downstream obligations to other investors and will raise questions with your Series A lead about cap table hygiene.
Founders can decline to accommodate SAFE investor demands when those demands are not supported by the SAFE or any side letter, when accommodating them would create MFN obligations to other SAFE investors, or when the investor's claim is simply that they want better economics than they negotiated. The SAFE is a contract — if the investor wants something not in the contract, they are asking for a gift, not asserting a right.
The clearest case for declining a SAFE investor's demands is when those demands are purely opportunistic — the investor saw the Series A headline and decided they want a better deal than they signed. In my experience, the correct response in this situation is professional but firm: the SAFE is a binding contract, its conversion mechanics are clear, and the company intends to honor the SAFE as written. If the investor believes the company is in breach of the SAFE or any side letter, they should identify the specific provision they believe has been violated and the company will address it. If they are simply asserting that they want better terms, the company is not obligated to provide them. The risk founders fear — the SAFE investor contacting the Series A lead and creating problems — is real but manageable. Your lead will have reviewed your cap table and understands SAFE mechanics. If a SAFE investor contacts them with complaints, your lead will almost certainly ask you about it, you will explain the situation, and if your position is legally correct, the lead will typically defer to you. What the lead will not want to see is a cap table dispute that wasn't disclosed, or evidence that you made special side deals with some SAFE investors and not others. The best protection against all of these scenarios is clean documentation, consistent treatment of SAFE investors, and direct early communication.
To prevent SAFE investor disputes in future rounds, founders should avoid granting side letters with unusual rights, use uniform SAFE terms across all investors in a round, ensure MFN clauses are limited in duration or scope, and set pro-rata rights at a level the company can honor consistently. The most problematic SAFEs are those with individually negotiated side letters that create rights not visible on the face of the SAFE.
The lessons from a difficult SAFE investor experience are usually expensive to learn but valuable to keep. In structuring future SAFEs, I advise founders on five points. First, use standard YC post-money SAFEs wherever possible and resist investor requests to modify the core economic terms. The standard form is well understood by Series A investors, requires no negotiation, and gives investors appropriate rights without creating unusual leverage. Second, if you must grant a side letter, limit it to pro-rata participation rights and standard information rights — do not grant MFN clauses if you can avoid them, because they create obligations that cascade across all other SAFE investors. Third, if you do have MFN clauses, track them carefully and comply with them in real time as you issue new SAFEs. An MFN violation discovered at Series A closing is a crisis; an MFN that was handled properly at the time is a non-issue. Fourth, set pro-rata rights at a level you can actually honor given realistic Series A sizing. Pro-rata rights that collectively exceed the amount of the new round create a math problem that will need to be negotiated. Fifth, keep your cap table clean and current — founders who can produce an accurate SAFE summary at any time with conversion mechanics clearly documented are far less vulnerable to investor disputes than founders whose cap table is a collection of individually negotiated documents that nobody has fully mapped.
I've seen founders lose weeks of their life to SAFE investors who were making demands they had no legal right to make. In almost every case, the investor's leverage came not from their legal rights but from the founder's uncertainty about what those rights were. Knowing your documents is the entire game here. If you know what your SAFEs say, you can have a direct and confident conversation with a difficult investor without blinking. If you're not sure what your SAFEs say, that uncertainty becomes leverage for the investor. Read your SAFEs before you're in a dispute — and if you don't understand them, ask your lawyer to explain the conversion mechanics before your next financing is imminent.
Gurpreet S. Bal is a Partner at Foley and Lardner LLP in Silicon Valley, where he advises startups, founders, and investors on SAFE financings, venture capital rounds, mergers and acquisitions, acquihires, and IPOs. He has represented clients in hundreds of transactions with aggregate deal value exceeding $60 billion across AI, semiconductors, fintech, and emerging technology. Prior to his career as a corporate lawyer and transaction advisor, he served with the U.S. Department of Justice and as an international and cross-border tax advisor at a Big 4 accounting firm.